Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

Autologous tandem transplantation: almost complete reduction of neutropenic fever following the second transplantation by ex vivo expanded autologous myeloid postprogenitor cells

Summary:

Reduced post-transplant performance status because of infectious complications is still a problem following autologous peripheral blood stem cell transplantation (aPBSCT). In this study, a tandem transplantation scheme for 15 patients with breast cancer including etoposide (1500 mg/m2), ifosfamide (12 g/m2) and carboplatin (1500 mg/m2) as conditioning regimens, followed by aPBSCT, was used to evaluate the potential clinical benefit of the additional retransfusion of low numbers of ex vivo expanded committed myeloid postprogenitor cells (PPCs) (median 408 × 103 CFU-c/kg BW, range 0.93–1995) following the second transplantation. Following a 7+2 days expansion (using recombinant human SCF, IL-1β, IL-3, IL-6 + G-CSF), CFU-c generated from CD34-positive cells from leukapheresis products could be expanded by a median factor of 153 (range 5–434). Flow cytometric analysis and morphology of CFUs have shown a nearly exclusive expansion and differentiation of committed myeloid progenitor cells and a significant reduction of CD34-positive cells. In an intra- and interindividual comparison it could be shown that the retransfusion of committed myeloid postprogenitor cells significantly accelerates myeloid recovery. Although retransfusion of PPCs fails to abrogate severe neutropenia following aPBSCT, it significantly ameliorates infectious complications and shortens the duration of hospital stay.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Reich G, Mapara MY, Reichardt P et al. Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors. Bone Marrow Transplant 2001; 27: 525–529.

    Article  CAS  PubMed  Google Scholar 

  2. Offidani M, Corvatta L, Olivieri A et al. Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF. Bone Marrow Transplant 1999; 24: 1079–1087.

    Article  CAS  PubMed  Google Scholar 

  3. Schmitz N, Linch DC, Dreger P et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353–357.

    Article  CAS  PubMed  Google Scholar 

  4. Ketterer N, Salles G, Raba M et al. High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998; 91: 3148–3155.

    CAS  PubMed  Google Scholar 

  5. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961–3969.

    CAS  PubMed  Google Scholar 

  6. Weisdorf DJ, Verfaillie CM, Davies SM et al. Hematopoietic growth factors for graft failure after bone marrow transplantation: a randomized trial of granulocyte-macrophage colony- stimulating factor (GM-CSF) versus sequential GM-CSF plus granulocyte- CSF. Blood 1995; 85: 3452–3456.

    CAS  PubMed  Google Scholar 

  7. Reiffers J, Cailliot C, Dazey B et al. Abrogation of post-myeloablative chemotherapy neutropenia by ex-vivo expanded autologous CD34-positive cells. Lancet 1999; 354: 1092–1093.

    Article  CAS  PubMed  Google Scholar 

  8. Koc ON, Gerson SL, Cooper BW et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000; 18: 307–316.

    Article  CAS  PubMed  Google Scholar 

  9. Possinger K, Wilmanns W . Palliative therapeutic control of tumor progression in patients with metastatic breast cancer. Internist (Berl) 1993; 34: 340–350.

    CAS  Google Scholar 

  10. Waller CF, von Lintig F, Daskalakis A, Musahl V, Lange W . Mobilization of peripheral blood progenitor cells in patients with breast cancer: a prospective randomized trial comparing rhG-CSF with the combination of rhG-CSF plus rhEpo after VIP-E chemotherapy. Bone Marrow Transplant 1999; 24: 19–24.

    Article  CAS  PubMed  Google Scholar 

  11. Haylock DN, To LB, Dowse TL et al. Ex vivo expansion and maturation of peripheral blood CD34+ cells into the myeloid lineage. Blood 1992; 80: 1405–1412.

    CAS  PubMed  Google Scholar 

  12. Sutherland HJ, Eaves AC, Eaves CJ . Quantitative assays for human hematopoietic progenitor cells. In: Gee A (ed.). Bone Marrow Processing and Purging: A Practical Guide. CRC Press Inc.: Boca Raton, 1991, pp. 155–171.

    Google Scholar 

  13. Metcalf D . Clonal culture of hematopoietic cells: techniques and applications. Elsevier: Amsterdam, 1984.

    Google Scholar 

  14. Sutherland DR, Anderson L, Keeney M et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996; 5: 213–226.

    Article  CAS  PubMed  Google Scholar 

  15. Olweus J, Lund Johansen F, Terstappen LW . Expression of cell surface markers during differentiation of CD34+, CD38-/lo fetal and adult bone marrow cells. Immunomethods 1994; 5: 179–188.

    Article  CAS  PubMed  Google Scholar 

  16. Piatier-Tonneau D . CD4 Workshop Panel report. In: Kishimoto T, Kikutani H, von dem Borne AE, Goyert SM, Mason D, Miyasaka M. (eds.). Leukocyte Typing IV. Garland Publishing: New York, London, 1997, pp. 49–54.

    Google Scholar 

  17. Paquette RL, Dergham ST, Karpf E et al. Ex vivo expanded unselected peripheral blood: progenitor cells reduce posttransplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancer. Blood 2000; 96: 2385–2390.

    CAS  PubMed  Google Scholar 

  18. McNiece I, Jones R, Bearman SI et al. Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer. Blood 2000; 96: 3001–3007.

    CAS  PubMed  Google Scholar 

  19. Scheding S, Franke H, Diehl V et al. How many myeloid post-progenitor cells have to be transplanted to completely abrogate neutropenia after peripheral blood progenitor cell transplantation? Results of a computer simulation. Exp Hematol 1999; 27: 956–965.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The study was supported by Deutsche Krebshilfe. We thank Mrs Linda Gatsch and Mrs Sylvia Kirchner for excellent technical assistance. We thank Dr Rajshri Jayaraman and Dr Harald Wagner for reading the manuscript and for their helpful comments.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reichle, A., Zaiss, M., Rothe, G. et al. Autologous tandem transplantation: almost complete reduction of neutropenic fever following the second transplantation by ex vivo expanded autologous myeloid postprogenitor cells. Bone Marrow Transplant 32, 299–305 (2003). https://doi.org/10.1038/sj.bmt.1704126

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704126

Keywords

This article is cited by

Search

Quick links